Xequel Bio selects Societal CDMO to support clinical development of iNexin

Published on May 12, 2023

Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.

Continue reading on website
Other news

UCB partners with Ariceum for treatment of immune-related diseases and cancer

May 12, 2023
UCB and Ariceum have announced a strategic research collaboration to identify and develop systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases.

Servier receives European Commission marketing approval for leukemia drug

May 12, 2023
Servier has received marketing approval from the European Commission (EC) for Tibsovo (ivosidenib tablets) to treat isocitrate dehydrogenase-1 (IDH1)-mutated acute myeloid leukaemia (AML) and IDH1-mutated cholangiocarcinoma.